UMN Startup Could Shake Up Medical Device Market
A new University of Minnesota startup company is aiming to commercialize two revolutionary cardiovascular-related products.
Vascudyne, launched by the University of Minnesota Technology Commercialization department, plans to develop bioengineered tissue using research by Dr. Robert Tranquillo.
“We are excited about the prospects of this material [becoming] a clinical reality with its commercialization by Vascudyne,” said Dr. Tranquillo, Stem Cell Institute.
The products offered by Vascudyne have regenerative capabilities which are unmatched in the market today.
“Professor Tranquillo’s innovative cardiovascular tissue platform is well positioned to help the field take this important step into the future,” said Luke Brewster in an interview with Twin Cities Business.
You may also like:
For many children, going to see Santa is one of the most exciting parts of Christmas. But for kids with autism, or sensory issues, the experience can be extremely scary.
Abnormal blood glucose values at hospital discharge linked to worse post-discharge outcomes.
New research by University of Minnesota scientists has revealed the three dimensional structure of the DUX4 protein, which is responsible for the disease, facioscapulohumeral muscular dystrophy (FSHD).